Lars Henning Engelholm
Sights set on targeted tumour killing
A dual assault on multiple types of cancer may be possible with a new cancer therapy developed by researchers at Rigshospitalet, Denmark’s largest hospital. By targeting both the cancer cells and the connective tissue cells around them, the therapy delivers a more precise double-strike.
Proverbially, a chain is only as strong as its weakest link. This is true of cancer, too. Inside a tumour, the malignant cells live side by side with connective tissue cells, benefiting from the support of these neighbouring cells. But the connective tissue cells are also a chink in the cancer ‘armour’ because they can be used to kill the cancer cells.
This is the premise for the development of a novel cancer therapy in a project led by Lars Henning Engelholm, MSc, at Rigshospitalet and the Biotech Research & Innovation Centre (BRIC), University of Copenhagen.
Read more about Lars Henning Engelholm's Frontier Grant:
A dual assault on multiple types of cancer may be possible with a new cancer therapy developed by researchers at Rigshospitalet...
